Direct comparison of HPV16 serological assays used to define HPV-naïve women in HPV vaccine trials

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 9, 2012, Pages 1547-1554

  Safaeian, Mahboobeh ^a   Ghosh, Arpita ^a   Porras, Carolina ^b   Lin, Shih Wen ^a   Rodriguez, Ana Cecilia ^b   Schiffman, Mark ^a   Wacholder, Sholom ^a   Kemp, Troy ^a   Gonzalez, Paula ^b   Wentzensen, Nicolas ^a   Esser, Mark ^e   Meuree, Ariane ^d   Matys, Katie ^f   Quint, Wim ^c   Van Doorn, Leen Jan ^c   Sherman, Mark E ^a   Herrero, Rolando ^b,g   Pinto, Ligia A ^a   Hildesheim, Allan ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b PROYECTO EPIDEMIOLÓGICO GUANACASTE   (Costa Rica)

^c DDL Diagnostic Laboratory   (Netherlands)

^d GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^e MEDIMMUNE   (United States)

^f PPD Vaccines and Biologics Center of Excellence   (United States)

^g INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; WART VIRUS VACCINE;

ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; COSTA RICA; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOASSAY; MAJOR CLINICAL STUDY; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; SEROLOGY; VIRION;

ANTIBODIES, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOASSAY; PAPILLOMAVIRUS VACCINES; VACCINATION;

EID: 84866153670     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-0558     Document Type: Article

References (22)

1. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65.
2. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
3. Lowy DR, Schiller JT. Reducing HPV-associated cancer globally. Cancer Prev Res 2012;5:18-23.
4. Munoz N, Kjaer SK, Sigurdsson K, Iversin OE, Hernandez-Avila M, Wheeler CM, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010;102:325-39.
5. Lehtinen M, Paavonen J, Wheeler CM, Jaisamram U, Garland SM, Castellsague X, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2011;13:89-99.
6. Opalka D, Lachman CE, MacMullen SA, Jansen KU, Smith JF, Chirmule N, et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 2003;10:108-15.
7. Dessy FJ, Giannini SL, Bougelet CA, Kemp TJ, David MP, Poncelet SM, et al. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin 2008;4:425-34.
8. Kemp TJ, Garcia-Pineres A, Falk RT, Poncelte S, Dessy F, Giannini SL, et al. Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine 2008;26:3608-16.
9. Krajden M, Cook D, Yu A, Chow R, Mei W, McNeil S, et al. Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial. Clin Vaccine Immunol 2011;18:418-23.
10. Smith JF, Kowalski R, Esser MT, Brown MJ, Bryan JT. Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil: a vaccine for human papillomavirus types 16, 18, 6 and 11. Hum Vaccin 2008;4:134-42.
11. Wentzensen N, Rodriguez AC, Viscidi R, Herrero R, Hildesheim A, Ghosh A, et al. A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study. J Infect Dis 2011;204:94-102.
12. Herrero R, Hildesheim A, Rodriguez AC, Wacholder S, Bratti C, Solomon D, et al. Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine 2008;26:4795-808.
13. Safaeian M, Porras C, Schiffman M, Rodriguez AC, Wacholder S, Gonzalez P, et al. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst 2010;102:1653-62.
14. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757-65.
15. Dias D, Van DJ, Schlottmann S, Kelly S, Puchalski D, Ruiz W, et al. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol 2005;12:959-69.
16. Kleter B, van Doorn LJ, ter SJ, Schrauwen L, van Krimpen K, Burger M, et al. Novel short-fragment PCR assay for highly sensitive broadspectrum detection of anogenital human papillomaviruses. Am J Pathol 1998;153:1731-9.
17. Kleter B, van Doorn LJ, Schrauwen L, Molijn A, Sastrowijoto J, Lindeman J, et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 1999;37:2508-17.
18. van Doorn LJ, Molijn A, Kleter B, Quint W, Colau B. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbiol 2006;44:3292-8.
19. Ferguson M, Wilkinson DE, Heath A, Matejtschuk P. The first international standard for antibodies to HPV 16. Vaccine 2011;29:6520-6.
20. Coseo S, Porras C, Hildesheim A, Rodriguez AC, Schiffman M, Herrero R, et al. Seroprevalence and correlates of human papillomavirus 16/18 seropositivity among young women in Costa Rica. Sex Transm Dis 2010;37:706-14.
21. Coseo SE, Porras C, Dodd LE, Hildesheim A, Rodriguez AC, Schiffman M, et al. Evaluation of the polyclonal ELISA HPV serology assay as a biomarker for human papillomavirus exposure. Sex Transm Dis 2011;38:976-82.
22. Wang SS, Schiffman M, Shields TS, Herrero R, Hildesheim A, Bratti MC, et al. Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica. Br J Cancer 2003;89:1248-54.